Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature

Title:Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature

Volume: 13 Issue: 3

Author(s): Devis Benfaremo, Lucia Manfredi, Michele Maria Luchetti*Armando Gabrielli

Affiliation:

• Dipartimento di Scienze Cliniche e Molecolari, Universita Politecnica delle Marche, Ancona,Italy

Keywords: Immune checkpoint inhibitors, anti-PD1, anti-CTLA4, nivolumab, pembrolizumab, ipilimumab, rheumatic diseases, musculoskeletal diseases.

Abstract: Background: Immune checkpoint inhibitors are a new promising class of antitumor drugs that have been associated with a number of immune-related Adverse Events (AEs), including musculoskeletal and rheumatic disease.

Methods: We searched Medline reviewing reports of musculoskeletal and rheumatic AEs induced by immune checkpoint inhibitors.

Results: Several musculoskeletal and rheumatic AEs associated with immune checkpoint inhibitors treatment are reported in the literature. In particular, arthralgia and myalgia were the most common reported AEs, whereas the prevalence of arthritis, myositis and vasculitis is less characterized and mainly reported in case series and case reports. Other occasionally described AEs are sicca syndrome, polymyalgia rheumatica, systemic lupus erythematosus and sarcoidosis.

Conclusion: Newly induced musculoskeletal and rheumatic diseases are a frequent adverse event associated with immune checkpoint inhibitors treatment.

Cite this article as:

Benfaremo Devis, Manfredi Lucia, Luchetti Maria Michele *, Gabrielli Armando, Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature, Current Drug Safety 2018; 13 (3) . https://dx.doi.org/10.2174/1574886313666180508122332